HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.

Isabel Aragón,Daniel Khalaf,Rebeca Lozano,Matti Annala,Sinja Taavitsainen,David Lorente,Daygen L. Finch,Nuria Romero Laorden,Joanna Vergidis,Ylenia Cendón,Conrad D. Oja,M. I. Pacheco,Muhammad Zulfiqar,Martin E. Gleave,Alexander W. Wyatt,David Olmos,Elena Castro,Kim N. Chi

HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.

2020

Isabel Aragón
Daniel Khalaf
Rebeca Lozano
Matti Annala
Sinja Taavitsainen
David Lorente
Daygen L. Finch
Nuria Romero Laorden
Joanna Vergidis
Ylenia Cendón
Conrad D. Oja
M. I. Pacheco
Muhammad Zulfiqar
Martin E. Gleave
Alexander W. Wyatt
David Olmos
Elena Castro
Kim N. Chi

5525Background: The common HSD3B1 (1245A > C) germline variant is associated with increased de-novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy in met...

Keywords:

Oncology
Enzalutamide
Abiraterone acetate
Internal medicine
Polymorphism (computer science)
Prostate cancer
HSD3B1
Pathology
Prospective cohort study
castration resistant
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations